Another Priority Review Voucher purchased! Biohaven Pharmaceutical Holding bought a PRV for $105 million from GW Research and will use it for priority review of its new anti-migraine drug, rimegepant Zydis.
The PRV program, established under the Creating Hope Act in 2012, encourages development of new drug and biological products for rare pediatric diseases. A company that develops a rare pediatric disease product receives a Priority Review Voucher from FDA that can be used for a faster review of its next drug, or it can be sold.
The PRV program = More drugs for rare pediatric diseases + Faster approval of potential blockbuster therapies.
Read more here.